Inclusion preparation of levosimendan and beta cyclodextrin
A β-cyclodextrin and cyclodextrin technology, which is applied in the field of anti-heart failure drug-β-cyclodextrin inclusion preparations, can solve problems such as poor effect, and achieve the effects of strong solubility, simple operation and good stability
Inactive Publication Date: 2005-11-02
王思清
View PDF5 Cites 11 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
The levosimendan preparation that has been on the market is levosimendan-KollidonPF12 injection. However, the Chinese Pharmacopoeia 2000 edition does not include KollidonPF12 as a non-vascular excipient. It is reported that KollidonPF12 is not effective as a solubilizing and stabilizing agent
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0029] Levosimendan 2.5 mg / ml, hydroxypropyl β-cyclodextrin 50 mg / ml, and ethanol for injection 5 ml were dissolved to obtain a solution for injection.
Embodiment 2
[0031] Levosimendan 2.5mg / ml, hydroxypropyl beta cyclodextrin 50mg / ml, citrate 2mg / ml, and ethanol for injection 5ml are dissolved to obtain a solution for injection.
Embodiment 3
[0033] Levosimendan 2.5 mg / ml, hydroxypropyl β-cyclodextrin 50 mg / ml, dissolved in 5 ml of ethanol for injection, filtered, and vacuum-dried to obtain levosimendan-hydroxypropyl β-cyclodextrin inclusion compound dry powder.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More Abstract
The present invention relates to one kind of heart failure resisting medicine, cyclodextrin or its derivative included preparation of levosimendan. The preparation has calcium-sensitive positive muscle medicine levosimendan as main component, and beta-cyclodextrin or its derivative, such as hydroxypropyl beta-cyclodextrin as including matter.
Description
Technical field: [0001] The invention relates to an anti-heart failure drug-beta-cyclodextrin inclusion preparation, in particular to a calcium-sensitive positive inotropic drug levosimendan as the main molecule and hydroxypropyl beta-cyclodextrin as the guest molecule. preparation. technical background: [0002] Levosimendan, chemical name [(4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono]malononitrile, Its structural formula is as follows: [0003] [0004] Levosimendan is a calcium-sensitizing myocardial inotrope mainly used in the treatment of congestive heart failure. Its preparation method is found in EP56556B1, WO97 / 35841, WO01 / 19334, WO98 / 01111, CN1470238A. Levosimendan is yellow powder crystal, slightly soluble in water, pKa is 6.26, solubility in phosphate buffer (pH7.4) is 0.4mg / ml, solubility in water at pH6 and pH2 is 0.03mg / ml and 0.02 respectively mg / ml; insoluble and easily degradable in water. The levosimendan preparation that has...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/50
Inventor 王思清毛白杨
Owner 王思清
PatSnap Eureka turns technology decisions into work you can execute. Powered by our Innovation Knowledge Graph, it runs expert workflows across engineering, life sciences, materials and intellectual property. Get your review-ready output in minutes.
